Most TSC caregivers plan to continue Epidiolex due to benefits like fewer seizures and improved cognition. New data at AES 2024 underscores Epidiolex's positive impact on TSC patients' health and well ...

– Age-range for all EPIDIOLEX indications expanded to include patients one year of age and older – – Third indication approved for EPIDIOLEX, the only FDA-approved Cannabidiol (CBD) medicine – ...

Please provide your email address to receive an email when new articles are posted on . LOS ANGELES — Treatment with cannabidiol led to improved seizure and nonseizure outcomes in patients with ...

Please provide your email address to receive an email when new articles are posted on . Survey responses reflected positive language and communication outcomes after cannabidiol use. Further ...

Data from nine abstracts to be presented, including first data from the EpiCom Trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, which suggests ...

The Company plans to discontinue further clinical development of ganaxolone in TSC. Marinus Pharmaceuticals announced that its phase 3 trial of ganaxolone did not meet the primary end point for the ...

How Does Epidiolex Work for Seizures? Seizures are caused by sudden electrical activity changes in the brain. These changes are temporary but result in changes in movement, behavior, sensation, or ...

LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved ...

Tuberous sclerosis complex is a multisystem disorder in which neurologic problems cause the greatest disability. High rates of mental retardation and autism spectrum disorders are associated with the ...

Lisa Ratledge can still remember the sleepless nights fueled by the fear that her young son might have a seizure while she was asleep and die in his bed. She became tearful at the memory of her son, ...